{"id":58765,"date":"2026-08-22T18:31:21","date_gmt":"2026-08-22T13:01:21","guid":{"rendered":"https:\/\/financialtelegraph.in\/index.php\/2026\/08\/22\/zeon-lifesciences-secures-us-fda-approval-strengthening-export-readiness-for-the-u-s-market\/"},"modified":"2026-08-22T18:31:21","modified_gmt":"2026-08-22T13:01:21","slug":"zeon-lifesciences-secures-us-fda-approval-strengthening-export-readiness-for-the-u-s-market","status":"publish","type":"post","link":"https:\/\/financialtelegraph.in\/index.php\/2026\/08\/22\/zeon-lifesciences-secures-us-fda-approval-strengthening-export-readiness-for-the-u-s-market\/","title":{"rendered":"Zeon Lifesciences Secures US FDA Approval, Strengthening Export Readiness for the U.S. Market"},"content":{"rendered":"
\n

\"Zeon<\/p>\n

New Delhi [India], August 22:<\/strong><\/strong> Zeon Lifesciences<\/a><\/strong> has successfully cleared inspections by U.S. Food and Drug Administration (U.S. FDA)<\/strong> for its manufacturing facility under the FSMA (Food Safety Modernization Act)<\/strong>, marking a significant regulatory milestone in the company\u2019s strategy to expand its international presence and strengthen its capabilities as a globally competitive nutraceutical and health supplements manufacturing partner.<\/p>\n

This follows the company\u2019s earlier U.S. FDA facility registration and builds on Zeon\u2019s continued investment in robust manufacturing systems, regulatory compliance, and quality processes. For facilities manufacturing, processing, packing or holding food, including dietary supplements, for consumption in the United States, FDA registration and compliance form part of the regulatory framework governing access to the U.S. market.<\/p>\n

The milestone follows Zeon\u2019s broader efforts to align its manufacturing operations with internationally recognised standards. The company has also secured NSF certification against the requirements of 21 CFR Part 111<\/strong>, the U.S. FDA\u2019s current Good Manufacturing Practice (cGMP) regulations for dietary supplements, further strengthening its quality and compliance credentials.<\/p>\n

Commenting on the development, Mr. Suresh Garg, Founder and Managing Director, Zeon Lifesciences<\/a><\/strong>, said, \u201cThis is an important step in our journey towards building a truly global nutraceutical manufacturing business. Our objective is not simply to enter international markets, but to build the manufacturing capabilities, quality systems and regulatory preparedness required to serve them responsibly. This milestone strengthens our readiness to engage with international customers and supports our long-term vision of positioning Zeon as a trusted manufacturing partner for global nutraceutical brands.\u201d<\/em><\/p>\n

This is expected to strengthen Zeon\u2019s ability to engage with international brands, distributors and contract manufacturing customers seeking manufacturing partners that understand and operate within U.S. regulatory requirements. It also supports the company\u2019s broader export strategy, while individual products and shipments remain subject to applicable product-specific regulatory, labelling and import requirements in the destination market.<\/p>\n

As part of its export-readiness programme, Zeon is strengthening processes related to U.S.-compliant packaging and artwork, finished-product testing and analysis, documentation and quality systems<\/strong>. These measures are intended to support the company\u2019s ability to develop and manufacture products for regulated international markets while maintaining consistent quality across its operations.<\/p>\n

This forms part of Zeon\u2019s longer-term strategy to build a globally competitive manufacturing platform across its nutraceutical portfolio. The company sees growing opportunities to work with international brands and partners seeking reliable Contract Development and Manufacturing Organisation (CDMO)<\/strong> capabilities from India, while continuing to expand its manufacturing and product-development capabilities.<\/p>\n

For Zeon, the milestone represents more than a regulatory requirement. It is part of a wider growth strategy centred on strengthening compliance, investing in manufacturing infrastructure and quality systems, and creating the foundation for sustained expansion into international markets.<\/p>\n

About Zeon Lifesciences<\/h3>\n

Zeon Lifesciences<\/strong><\/a> is India\u2019s leading manufacturer of nutraceutical and Ayurvedic products and one of the country\u2019s largest Contract Development and Manufacturing Organisations (CDMO). With almost four decades of experience, the company has been serving the nutrition, wellness and Ayurvedic sectors through a focus on scientific innovation, stringent quality standards and customer-centric manufacturing.<\/p>\n

Zeon <\/a><\/strong>has established strategic collaborations with leading research organisations for technology transfer, patent filing and clinical validation. Its clients include MyProtein, Danone Nutricia, Dr. Reddy\u2019s, Fresenius Kabi, Forever, Sun Pharma, Herbalife, Tata Consumer Products, Decathlon, Himalaya, Kepler, Cipla, GNC, Bright Lifecare and Modicare,<\/strong> among several other leading brands.<\/p>\n

If you object to the content of this press release, please notify us at pr.error.rectification@gmail.com. We will respond and rectify the situation within 24 hours.<\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

New Delhi [India], August 22: Zeon Lifesciences has successfully cleared inspections by U.S. Food and Drug Administration (U.S. FDA) for its manufacturing facility under the FSMA (Food Safety Modernization Act), … Read More<\/a><\/p>\n","protected":false},"author":1,"featured_media":58766,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[448],"class_list":["post-58765","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","tag-business","entry"],"_links":{"self":[{"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/posts\/58765","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/comments?post=58765"}],"version-history":[{"count":0,"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/posts\/58765\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/media\/58766"}],"wp:attachment":[{"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/media?parent=58765"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/categories?post=58765"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/tags?post=58765"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}